Catalyst Pharmaceuticals Stock News

Catalyst Pharmaceuticals (NASDAQ:CPRX) is scheduled to announce Q4 earnings results on Wednesday, March 16th, after market close.The consensus EPS Estimate is $0.12 (+9.1% Y/Y) and…

Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensi

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

The Company Ranked 65th of More Than 1,000 Companies Assessed The Company Ranked 65th of More Than 1,000 Companies Assessed

CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX ), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the Company is named on Forbes 2022 "America''s Best Small Companies" in its recently published list. The Company was ranked 65th of more than 1,000 companies evaluated. "It is a distinguished honor to be recognized by Forbes as one of the country''s best small companies," said Patrick J. McEnany, Chairman and CEO of Catalyst. "Our strong operating and financial performance result from our exceptional commercial and strategic execution. Having acknowledgment of the value we are creating is very gratifying, and I would like to thank all of our employees who share a commitment to the rare disease patients we serve." Forbes 2022 America''s Best Small-Cap Companies annual list was …

Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET